Funding for this research was provided by:
Natural Science Foundation of Liaoning Province (2019-MS-03)
Key Technologies Research and Development Program (Molecular mechanism of KLHL18 inhibiting proliferation of lung cancer cells by MEK/ERK)
Received: 12 August 2020
Accepted: 17 November 2020
First Online: 27 November 2020
Ethics approval and consent to participate
: This study was approved by the Medical Research Ethics Committee of China Medical University.
: All recruited patients provided informed consent.
: The authors declare that they have no competing interests.